{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:50:33Z","timestamp":1791838233325,"version":"4.3.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rising metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence parallels increased sugar-sweetened beverage (SSB) consumption. Clinical studies suggest differential metabolic effects of fructose, glucose, and sucrose, yet their distinct roles in MASLD pathogenesis remain uncharacterized in preclinical models. This study aimed to establish a murine model to dissect the specific contributions of fructose, glucose, and sucrose to MASLD progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study establishes a murine model to dissect SSB-specific contributions to MASLD progression. Eight-week-old male C57BL\/6N mice were fed a high-fat high-cholesterol (HFHC) diet with\/without fructose-, glucose-, or sucrose-sweetened beverages for 10 weeks. Hepatic transcriptomic profiles were analyzed via microarray, followed by functional enrichment. Protein-protein interaction (PPI) network and single-cell analysis identify pathway perturbations and hub genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fructose-SB supplementation, unlike glucose or sucrose, exacerbated HFHC-induced MASLD phenotypes, including elevated body weight, hepatic steatosis, glucose intolerance, and hepatocellular injury. Transcriptomics identified 2,195 fructose-specific differentially expressed genes (DEGs: 1,978 upregulated, 224 downregulated). Upregulated DEGs were enriched in thyroid hormone signaling, lysosomal activity, and autophagy, while downregulated DEGs implicated oxidative phosphorylation suppression. PPI analysis revealed key hub genes (Akt1, Stat3, Ctnnb1, Ep300) and mitochondrial components (mt-Nd4, mt-Cytb, Uqcrq) as central regulators of fructose-driven pathology. Fructose-SB uniquely accelerates MASLD progression in HFHC-fed mice through transcriptional reprogramming of metabolic and mitochondrial pathways. In mice fed a high-fructose diet, expression of key hub genes was elevated, particularly in Kupffer and endothelial cells, which were also enriched in proportion. These findings highlight fructose-specific mechanisms in MASLD pathogenesis and identify potential therapeutic targets for SSB-associated metabolic disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2025.1710267","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:13Z","timestamp":1764739213000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of the role of sugar-sweetened beverages in the progression of a murine metabolic dysfunction-associated steatotic liver disease model"],"prefix":"10.3389","volume":"12","author":[{"given":"Yong-Qiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.14218\/JCTH.2024.00311","article-title":"Chinese society of hepatology CMA. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024)","volume":"12","author":"Fan","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s13105-023-00954-4","article-title":"de la Torre Alaez M, Sangro B, D'Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment","volume":"79","author":"Sangro","year":"2023","journal-title":"J Physiol Biochem"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2139\/ssrn.4438001","article-title":"Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis","volume":"22","author":"Cao","year":"2024","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s12072-023-10568-z","article-title":"Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes","volume":"17","author":"Vaz","year":"2023","journal-title":"Hepatol Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12072-024-10667-5","article-title":"The contribution of genetics and epigenetics to MAFLD susceptibility","volume":"18","author":"Moretti","year":"2024","journal-title":"Hepatol Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1017\/S136898001500066X","article-title":"Focus on sugar-sweetened beverages","volume":"18","author":"Caballero","year":"2015","journal-title":"Public Health Nutr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3390\/ijerph16122192","article-title":"Consumption of sugar-sweetened beverages has a dose-dependent effect on the risk of non-alcoholic fatty liver disease: an updated systematic review and dose-response meta-analysis","volume":"16","author":"Chen","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1172\/JCI37385","article-title":"Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans","volume":"119","author":"Stanhope","year":"2009","journal-title":"J Clin Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jhep.2021.02.027","article-title":"Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: a randomized controlled trial","volume":"75","author":"Geidl-Flueck","year":"2021","journal-title":"J Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1053\/j.gastro.2013.07.012","article-title":"No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men","volume":"145","author":"Johnston","year":"2013","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"115690","DOI":"10.1016\/j.celrep.2025.115690","article-title":"Multitissue single-cell analysis reveals differential cellular and molecular sensitivity between fructose and high-fat high-sucrose diets","volume":"44","author":"Chen","year":"2025","journal-title":"Cell Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41574-021-00627-6","article-title":"The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases","volume":"18","author":"Malik","year":"2022","journal-title":"Nat Rev Endocrinol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","article-title":"Fructose stimulated de novo lipogenesis is promoted by inflammation","volume":"2","author":"Todoric","year":"2020","journal-title":"Nat Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1210\/jc.2013-3856","article-title":"Sugar-sweetened beverages with moderate amounts of fructose, but not sucrose, induce Fatty Acid synthesis in healthy young men: a randomized crossover study","volume":"99","author":"Hochuli","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.tem.2016.06.005","article-title":"The sweet path to metabolic demise: fructose and lipid synthesis","volume":"27","author":"Herman","year":"2016","journal-title":"Trends Endocrinol Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrgastro.2010.41","article-title":"The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome","volume":"7","author":"Lim","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41401-021-00629-0","article-title":"Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacol Sin."},{"key":"B18","doi-asserted-by":"publisher","first-page":"eabh3839","DOI":"10.1126\/scisignal.abh3839","article-title":"Thyroid hormone signaling promotes hepatic lipogenesis through the transcription factor ChREBP","volume":"14","author":"Mendoza","year":"2021","journal-title":"Sci Signal"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e12240","DOI":"10.1590\/1414-431x2022e12240","article-title":"Fructose consumption induces molecular adaptations involving thyroid function and thyroid-related genes in brown adipose tissue in rats","volume":"55","author":"Neto","year":"2023","journal-title":"Braz J Med Biol Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"796207","DOI":"10.3389\/fphar.2021.796207","article-title":"Mitochondrial targeting therapeutics: promising role of natural products in non-alcoholic fatty liver disease","volume":"12","author":"Xu","year":"2021","journal-title":"Front Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hep.1840380426","article-title":"Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis","volume":"38","author":"Perez-Carreras","year":"2003","journal-title":"Hepatology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/hep.21313","article-title":"Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob\/ob mice","volume":"44","author":"Garcia-Ruiz","year":"2006","journal-title":"Hepatology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/dmm.016766","article-title":"High-fat diet decreases activity of the oxidative phosphorylation complexes and causes nonalcoholic steatohepatitis in mice","volume":"7","author":"Garcia-Ruiz","year":"2014","journal-title":"Dis Model Mech."},{"key":"B24","article-title":"Biochemistry, fructose metabolism","author":"Dholariya","year":"2025"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100638","DOI":"10.1016\/j.bbrep.2019.100638","article-title":"Acute fructose intake suppresses fasting-induced hepatic gluconeogenesis through the AKT-FoxO1 pathway","volume":"18","author":"Sato","year":"2019","journal-title":"Biochem Biophys Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clnesp.2025.06.042","article-title":"The metabolic and molecular mechanisms linking fructose consumption to lipogenesis and metabolic disorders","volume":"69","author":"Baharuddin","year":"2025","journal-title":"Clin Nutr ESPEN."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1053\/j.gastro.2015.02.056","article-title":"Beta-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis","volume":"148","author":"Monga","year":"2015","journal-title":"Gastroenterology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"101186","DOI":"10.1016\/j.jhepr.2024.101186","article-title":"Development of mutated \u03b2-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC","volume":"6","author":"Lehrich","year":"2024","journal-title":"JHEP Reports."},{"key":"B29","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.clinbiochem.2016.01.025","article-title":"Genetic polymorphisms in the Wnt\/beta-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"49","author":"Kim","year":"2016","journal-title":"Clin Biochem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1479164117738442","article-title":"Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseases","volume":"15","author":"Ackers","year":"2018","journal-title":"Diab Vasc Dis Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.hbpd.2022.10.003","article-title":"Wnt\/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases","volume":"22","author":"Shree Harini","year":"2023","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.bbrc.2020.03.147","article-title":"Activation of Wnt\/beta-catenin pathway causes insulin resistance and increases lipogenesis in HepG2 cells via regulation of endoplasmic reticulum stress","volume":"526","author":"Lei","year":"2020","journal-title":"Biochem Biophys Res Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics."},{"key":"B34","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.celrep.2013.02.009","article-title":"Increased expression of enzymes of triglyceride synthesis is essential for the development of hepatic steatosis","volume":"3","author":"Jin","year":"2013","journal-title":"Cell Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.5483\/BMBRep.2022-0188","article-title":"Therapeutic effects of selective p300 histone acetyl-transferase inhibitor on liver fibrosis","volume":"56","author":"Kim","year":"2023","journal-title":"BMB Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"42667","DOI":"10.18632\/oncotarget.5626","article-title":"The Akt1\/IL-6\/STAT3 pathway regulates growth of lung tumor initiating cells","volume":"6","author":"Malanga","year":"2015","journal-title":"Oncotarget."},{"key":"B37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.02.016","article-title":"Impaired translocation and activation of mitochondrial Akt1 mitigated mitochondrial oxidative phosphorylation complex V activity in diabetic myocardium","volume":"59","author":"Yang","year":"2013","journal-title":"J Mol Cell Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.redox.2018.101073+33","article-title":"Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors","volume":"25","author":"Lee","year":"2019","journal-title":"Redox Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"156507","DOI":"10.1016\/j.cyto.2024.156507","article-title":"EP300 improves endothelial injury and mitochondrial dysfunction in coronary artery disease by regulating histone acetylation of SOCS1 promoter via inhibiting JAK\/STAT pathway","volume":"176","author":"Xue","year":"2024","journal-title":"Cytokine."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1710267\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:14Z","timestamp":1764739214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1710267\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":39,"alternative-id":["10.3389\/fnut.2025.1710267"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2025.1710267","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1710267"}}